Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stake Decreased by RA Capital Management L.P.

RA Capital Management L.P. lowered its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 8.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,982,587 shares of the company's stock after selling 639,760 shares during the quarter. RA Capital Management L.P. owned 8.81% of Tenaya Therapeutics worth $13,476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in TNYA. abrdn plc acquired a new stake in Tenaya Therapeutics in the 3rd quarter valued at $1,063,000. Vanguard Group Inc. grew its stake in shares of Tenaya Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company's stock valued at $14,973,000 after buying an additional 403,472 shares in the last quarter. American Century Companies Inc. lifted its position in Tenaya Therapeutics by 27.7% during the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company's stock worth $317,000 after acquiring an additional 22,146 shares in the last quarter. Integral Health Asset Management LLC boosted its holdings in Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company's stock worth $7,208,000 after acquiring an additional 75,000 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Tenaya Therapeutics by 42.5% in the second quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company's stock valued at $316,000 after acquiring an additional 30,446 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company's stock.

Analyst Upgrades and Downgrades

TNYA has been the topic of a number of analyst reports. Leerink Partners reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a "buy" rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital dropped their price target on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a report on Monday, November 25th. Finally, Piper Sandler restated an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics has a consensus rating of "Buy" and a consensus price target of $17.33.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA traded down $0.09 during midday trading on Thursday, hitting $3.33. The company's stock had a trading volume of 2,300,632 shares, compared to its average volume of 1,073,371. Tenaya Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $7.01. The firm's fifty day moving average price is $2.23 and its 200-day moving average price is $2.81. The firm has a market cap of $263.80 million, a P/E ratio of -2.38 and a beta of 2.72.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, research analysts predict that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.